Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 BF2.649 for residual excessive daytime sleepiness in obstructive sleep apnea on nCPAP
jRCT2031220501Phase 3Completed
- Sponsor
- Aculys Pharma, Inc.
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pitolisant in obstructive sleep apnea hypopnea syndrome (OSAHS) (4 arms), sponsored by Aculys Pharma, Inc. Primary endpoint: Epworth Sleepiness Scale. Started Jan 2023; status: completed.
02
Drugs
pitolisant
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on jRCT2031220501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220501.